Mary E Enama

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Randomization to standard and concise informed consent forms: development of evidence-based consent practices
    Mary E Enama
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    Contemp Clin Trials 33:895-902. 2012
  2. pmc Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect
    Julie E Ledgerwood
    Vaccine Research Center, National Institute ofAllergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 208:418-22. 2013
  3. pmc Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire
    Joseph P Casazza
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, Maryland 20892, USA
    J Infect Dis 207:1829-40. 2013
  4. pmc DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    PLoS ONE 8:e59340. 2013
  5. doi request reprint DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
    Julie E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet Infect Dis 11:916-24. 2011

Detail Information

Publications5

  1. pmc Randomization to standard and concise informed consent forms: development of evidence-based consent practices
    Mary E Enama
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    Contemp Clin Trials 33:895-902. 2012
    ....
  2. pmc Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect
    Julie E Ledgerwood
    Vaccine Research Center, National Institute ofAllergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 208:418-22. 2013
    ..This study defines the shortest prime-boost interval associated with an improved response to MIV...
  3. pmc Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire
    Joseph P Casazza
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, Maryland 20892, USA
    J Infect Dis 207:1829-40. 2013
    ..The licensing of herpes zoster vaccine has demonstrated that therapeutic vaccination can help control chronic viral infection. Unfortunately, human trials of immunodeficiency virus (HIV) vaccine have shown only marginal efficacy...
  4. pmc DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    PLoS ONE 8:e59340. 2013
    ..DNA vaccine immunogenicity has been limited by inefficient delivery. Needle-free delivery of DNA using a CO2-powered Biojector® device was compared to delivery by needle and syringe and evaluated for safety and immunogenicity...
  5. doi request reprint DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
    Julie E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet Infect Dis 11:916-24. 2011
    ..We assessed the safety and immunogenicity of DNA encoding H5 as a priming vaccine to improve antibody responses to inactivated influenza vaccination...